印度尼西亚 Cipto Mangunkusumo 医院（CMH）中乳腺癌对新辅助治疗的反应中基质肿瘤浸润淋巴细胞（sTIL）强度和程序性死亡配体 1（）表达的作用。
The Role of Stromal Tumour Infiltrating Lymphocytes (sTIL) Intensity and Programmed Death Ligand 1 () Expression in Breast Cancer Response to Neoadjuvant Therapy in Cipto Mangunkusumo Hospital (CMH), Indonesia.
机构信息
Department of Anatomic Pathology, Faculty of Medicine Universitas Indonesia (FMUI)-Cipto Mangunkusumo Hospital (CMH), Jakarta, Indonesia.
出版信息
Asian Pac J Cancer Prev. 2023 Oct 1;24(10):3459-3465. doi: 10.31557/APJCP.2023.24.10.3459.
BACKGROUND
Pathological responses to neoadjuvant therapy were still relatively poor, especially in CMH. Studies had been done to search for predictors of response such as sTIL intensity and expression, which is known to block sTIL action in killing cancer cells. This research assessed sTIL intensity and expression as predictors of response to neoadjuvant therapy in breast cancer. The preliminary data might be used to better tailored breast cancer patient therapy, considering the availability of anti-PD-1/ PD- L1 immunotherapy nowadays.
OBJECTIVE
To assess TIL intensity, expressions, and their roles as pathological predictors of breast cancer response to neoadjuvant therapy in Cipto Mangunkusumo Hospital (CMH).
METHOD
This was an observational analytic retrospective cohort study on breast cancer patients undergoing biopsy/review of biopsy specimens, receiving neoadjuvant therapy and mastectomy in CMH from January 2014 to December 2021. Sixty cases fulfilled the inclusion and exclusion criteria. Total sampling was done. expression (immunohistochemistry, clone 22C3) and sTIL intensity (histopathology) was examined in the biopsy specimen. Linear regression analysis was done to determine the independent predictors of neoadjuvant therapy response (evaluated in the mastectomy specimen with residual cancer burden/ RCB score).
RESULTS
There were 60 female patients, median age 46 years old. 91,7% had invasive carcinoma of no special type. Median sTIL intensity was 10% (1%-70%). 58,3% patients had low sTIL intensity (≤10%). 28,3% patients had positive expression (CPS ≥1). Only 8,3% patients had pCR, while 90% patients had RCB class II-III. Every 1% increase in sTIL intensity, no lymphovascular invasion, and taxane chemotherapy were predicted to lower RCB score by 0,058, 0,781, dan 0,594, respectively. expression associated with pCR-RCB class I (p=0,048), but CPS score was not a predictor of RCB score in linear regression analysis.
CONSLUSION
sTIL intensity was an independent predictor of breast cancer response to neoadjuvant therapy in RSCM. expression associated with pCR-RCB class I, but CPS score was not a predictor of RCB score.
背景
新辅助治疗的病理反应仍然相对较差，尤其是在 CMH。已经进行了研究以寻找反应的预测因子，例如 sTIL 强度和表达，这些因子已知会阻断 sTIL 杀死癌细胞的作用。本研究评估了 sTIL 强度和表达作为新辅助治疗对乳腺癌反应的预测因子。鉴于目前抗 PD-1/PD-L1 免疫疗法的可用性，初步数据可能用于更好地定制乳腺癌患者的治疗。
目的
评估 TIL 强度、表达及其作为 Cipto Mangunkusumo 医院（CMH）乳腺癌对新辅助治疗反应的病理预测因子的作用。
方法
这是一项回顾性观察性分析队列研究，纳入了 2014 年 1 月至 2021 年 12 月在 CMH 接受活检/活检标本复查、新辅助治疗和乳房切除术的乳腺癌患者。符合纳入和排除标准的有 60 例。采用全抽样法。在活检标本中检测 表达（免疫组化，克隆 22C3）和 sTIL 强度（组织病理学）。采用线性回归分析确定新辅助治疗反应的独立预测因子（在乳房切除标本中评估，以残留癌负荷/RCB 评分表示）。
结果
共有 60 名女性患者，中位年龄 46 岁。91.7%为非特殊类型浸润性癌。中位 sTIL 强度为 10%（1%-70%）。58.3%的患者 sTIL 强度低（≤10%）。28.3%的患者 表达阳性（CPS≥1）。仅有 8.3%的患者达到 pCR，而 90%的患者为 RCB Ⅱ-Ⅲ级。sTIL 强度每增加 1%、无脉管侵犯和紫杉烷化疗分别预测 RCB 评分降低 0.058、0.781 和 0.594。表达与 pCR-RCB Ⅰ级相关（p=0.048），但 CPS 评分不是线性回归分析中 RCB 评分的预测因子。
结论
sTIL 强度是 RSCM 乳腺癌对新辅助治疗反应的独立预测因子。表达与 pCR-RCB Ⅰ级相关，但 CPS 评分不是 RCB 评分的预测因子。
Zotero 插件